| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
65,540,000 |
| Market
Cap: |
4.23(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$6.84 - $64.62 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 18.1 |
| Insider 3/6 Months : 18.7 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Alpine Immune Sciences is a clinical-stage biopharmaceutical company focused on discovering and developing protein-based immunotherapies to treat cancer and autoimmune and inflammatory diseases. Co.'s ALPN-101 (acazicolcept) is a dual Inducible T cell Costimulator and cluster of differentiation 28 (CD28) antagonist intended for the treatment of autoimmune and inflammatory diseases. Co.'s ALPN-303 is a dual B cell cytokine antagonist, being developed for the treatment of B cell mediated inflammatory and autoimmune diseases. Co.'s primary oncology program is ALPN-202 (davoceticept) is a conditional CD28 costimulator and dual checkpoint inhibitor intended for the treatment of cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
750,000 |
750,000 |
750,000 |
| Total Buy Value |
$0 |
$9,375,000 |
$9,375,000 |
$9,375,000 |
| Total People Bought |
0 |
2 |
2 |
2 |
| Total Buy Transactions |
0 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
3,587,510 |
3,587,510 |
3,587,510 |
| Total Sell Value |
$0 |
$66,911,481 |
$66,911,481 |
$66,911,481 |
| Total People Sold |
0 |
4 |
4 |
4 |
| Total Sell Transactions |
0 |
23 |
23 |
23 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Fuhs Ulrich Martin |
Chief Accounting OfficerOffice |
• – – |
2024-04-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
7,300 |
|
70% |
|
| Rickey James Paul |
See Remarks |
• – – |
2024-01-26 |
4 |
AS |
$22.31 |
$2,745,830 |
D/D |
(117,764) |
0 |
|
157% |
|
| Rickey James Paul |
See Remarks |
• – – |
2024-01-26 |
4 |
OE |
$6.51 |
$977,844 |
D/D |
117,764 |
44,000 |
|
- |
|
| Rickey James Paul |
See Remarks |
• – – |
2024-01-25 |
4 |
AS |
$22.00 |
$5,192 |
D/D |
(236) |
0 |
|
197% |
|
| Rickey James Paul |
See Remarks |
• – – |
2024-01-25 |
4 |
OE |
$6.51 |
$1,536 |
D/D |
236 |
236 |
|
- |
|
| Decheng Capital Management Iii (cayman), Llc |
10% Owner |
– – • |
2024-01-18 |
4 |
OE |
$12.74 |
$15,729,263 |
D/D |
1,234,636 |
6,582,380 |
|
- |
|
| Cui Xiangmin |
Director |
– • • |
2024-01-18 |
4 |
OE |
$12.74 |
$15,729,263 |
I/I |
1,234,636 |
6,582,380 |
|
- |
|
| Thompson Peter A |
Director |
– • – |
2024-01-11 |
4 |
OE |
$12.74 |
$1,850,498 |
I/I |
145,251 |
2,416,181 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2024-01-11 |
4 |
OE |
$12.74 |
$1,850,498 |
I/I |
145,251 |
2,416,181 |
|
- |
|
| Rickey James Paul |
See Remarks |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
31,200 |
31,200 |
|
- |
|
| Durand Remy |
Chief Business Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
31,200 |
38,104 |
|
- |
|
| Peng Stanford L |
See Remarks |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
48,000 |
72,371 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
96,000 |
96,000 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2023-12-28 |
4 |
S |
$18.32 |
$25,049,034 |
I/I |
(1,364,849) |
264,315 |
|
-230% |
|
| Thompson Peter A |
Director |
– • – |
2023-12-28 |
4 |
S |
$18.32 |
$25,049,034 |
I/I |
(1,364,849) |
264,315 |
|
-230% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-28 |
4 |
D |
$19.65 |
$948,388 |
I/I |
(48,264) |
2,627,157 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-28 |
4 |
OE |
$12.74 |
$948,378 |
I/I |
74,441 |
2,675,421 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-28 |
4 |
AS |
$20.04 |
$20,362 |
D/D |
(1,016) |
0 |
|
230% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-28 |
4 |
OE |
$0.65 |
$660 |
D/D |
1,016 |
1,016 |
|
- |
|
| Orbimed Genesis Gp Llc |
Director |
– • – |
2023-12-27 |
4 |
S |
$19.96 |
$3,622,700 |
I/I |
(181,498) |
406,609 |
|
-224% |
|
| Thompson Peter A |
Director |
– • – |
2023-12-27 |
4 |
S |
$19.96 |
$3,622,700 |
I/I |
(181,498) |
406,609 |
|
-224% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-27 |
4 |
AS |
$20.04 |
$592,717 |
D/D |
(29,573) |
0 |
|
224% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-27 |
4 |
OE |
$0.65 |
$19,222 |
D/D |
29,573 |
29,573 |
|
- |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-26 |
4 |
AS |
$20.22 |
$495,217 |
D/D |
(24,486) |
0 |
|
219% |
|
| Gold Mitchell |
Executive Chairman and CEO |
• • – |
2023-12-26 |
4 |
OE |
$0.45 |
$15,436 |
D/D |
24,486 |
24,486 |
|
- |
|
181 Records found
|
|
Page 1 of 8 |
|
|
0.06 (0.09%) 
